Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05968326 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Name: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC — clinical trial record (NCT05968326)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: IMCODE003

StatusActive, Not Recruiting

PhasePhase 2

SponsorGenentech, Inc.

Started2023-10-18

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

Amendment history 1 change detected by DataLookout

2026-09-10

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT05968326
Lead Sponsor	Genentech, Inc. Collaborators: BioNTech SE
Conditions	Adenocarcinoma, Pancreatic Ductal
Enrollment	260 participants
Start Date	2023-10-18
Primary Completion	2031-01-01 (estimated)
Study Completion	2031-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-09